First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers

被引：0
|
作者：
Wenham, R. M. [1 ,2 ]
Sandhu, S. K. [3 ]
Wilding, G. [4 ]
Sun, L. [5 ]
Toniatti, C. [5 ]
Stroh, M. [5 ]
Carpenter, C. [5 ]
de-Bono, J. [3 ]
Baird, R. [3 ]
Schelman, W. R. [4 ]
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Div Gynecol Oncol, Tampa, FL 33682 USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr, Div Expt Therapeut, Tampa, FL 33682 USA
[3] Royal Marsden NHS Fdn Trust, Drug Dev Unit, Sutton, Surrey, England
[4] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[5] Merck & Co Inc, Merck Res Labs, Whitehouse Stn, NJ USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72069-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：114 / 115
页数：2
相关论文
共 50 条
  • [31] Integrated safety analysis of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings
    Kristeleit, R. S.
    Oza, A. M.
    Oaknin, A.
    Aghajanian, C.
    Tinker, A. V.
    Tredan, O.
    O'Malley, D. M.
    Leary, A.
    Konecny, G. E.
    Lorusso, D.
    Weberpals, J. I.
    Goble, S.
    Maloney, L.
    Cameron, T.
    Swisher, E.
    McNeish, I. A.
    Shapira-Frommer, R.
    Ledermann, J. A.
    Coleman, R. L.
    ANNALS OF ONCOLOGY, 2019, 30 : 409 - +
  • [32] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
    Tutt, Andrew
    Robson, Mark
    Garber, Judy E.
    Domchek, Susan M.
    Audeh, M. William
    Weitzel, Jeffrey N.
    Friedlander, Michael
    Arun, Banu
    Loman, Niklas
    Schmutzler, Rita K.
    Wardley, Andrew
    Mitchell, Gillian
    Earl, Helena
    Wickens, Mark
    Carmichael, James
    LANCET, 2010, 376 (9737): : 235 - 244
  • [33] Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety
    Kristeleit, Rebecca S.
    Oaknin, Ana
    Ray-Coquard, Isabelle
    Leary, Alexandra
    Balmana, Judith
    Drew, Yvette
    Oza, Amit M.
    Shapira-Frommer, Ronnie
    Domchek, Susan M.
    Cameron, Terri
    Maloney, Lara
    Goble, Sandra
    Lorusso, Domenica
    Ledermann, Jonathan A.
    McNeish, Iain A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (09) : 1396 - 1404
  • [34] Recruitment experience in a phase 0 trial of ABT-888, an inhibitor of poly (ADP-ribose) polymerase (PARP), in patients (pts) with advanced malignancies
    Gutierrez, M.
    Kummar, S.
    Horneffer, Y.
    Juwara, L.
    Chen, A.
    Melillo, G.
    Pickeral, O.
    Tomaszewski, J. E.
    Murgo, A. J.
    Doroshow, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor (PARP) in patients with newly diagnosed ovarian cancer: A systematic review and meta-analysis.
    Stecca, Carlos
    Vilbert, Maysa
    Michelon, Isabella
    Castro, Caio
    Dacoregio, Maria Inez
    Fin, Fabio
    Tsunoda, Audrey Tieko
    De Melo, Andreia Cristina
    Da Costa, Alexandre Andre B. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and recurrent ovarian cancer
    Li, N.
    Bu, H.
    Liu, J.
    Zhu, J.
    Zhou, Q.
    Wang, L.
    Yin, R.
    Wu, X.
    Yao, S.
    Gu, K.
    Zhang, H.
    Li, G.
    Pan, H.
    Wu, Q.
    An, R.
    Yang, X.
    Zhu, Y.
    Wan, X.
    Duan, W.
    Xiong, J.
    Wang, Y.
    Wang, Q.
    Zou, J.
    Wu, L. Y.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 159 - 159
  • [37] Real-world Outcomes Associated With Poly(ADP-ribose) Polymerase Inhibitor Monotherapy Maintenance in Patients With Primary Advanced Ovarian Cancer
    Chan, John K.
    Liu, Jinan
    Song, Jinlin
    Xiang, Cheryl
    Wu, Eric
    Kalilani, Linda
    Hurteau, Jean A.
    Thaker, Premal H.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2023, 46 (07): : 314 - 322
  • [38] Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
    Lotte van Andel
    Z. Zhang
    S. Lu
    V. Kansra
    S. Agarwal
    L. Hughes
    M. M. Tibben
    A. Gebretensae
    L. Lucas
    M. J. X. Hillebrand
    H. Rosing
    J. H. M. Schellens
    J. H. Beijnen
    Investigational New Drugs, 2017, 35 : 751 - 765
  • [39] Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
    van Andel, Lotte
    Zhang, Z.
    Lu, S.
    Kansra, V.
    Agarwal, S.
    Hughes, L.
    Tibben, M. M.
    Gebretensae, A.
    Lucas, L.
    Hillebrand, M. J. X.
    Rosing, H.
    Schellens, J. H. M.
    Beijnen, J. H.
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 751 - 765
  • [40] Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
    Drew, Yvette
    Ledermann, Jonathan
    Hall, Geoff
    Rea, Daniel
    Glasspool, Ros
    Highley, Martin
    Jayson, Gordon
    Sludden, Julieann
    Murray, James
    Jamieson, David
    Halford, Sarah
    Acton, Gary
    Backholer, Zoe
    Mangano, Raffaella
    Boddy, Alan
    Curtin, Nicola
    Plummer, Ruth
    BRITISH JOURNAL OF CANCER, 2016, 114 (07) : 723 - 730
12345